脂肪性肝病的影像学评估
本文综述了超声、CT 和 MRI 在无创评估肝脂肪变性和纤维化中的原理、临床应用、效能及进展,并探讨了机器学习、机会性筛查、标准化影像指南和治疗方法等 MASLD 诊断新进展,强调放射科医生在其中可发挥的关键作用。
要点
- 超声、CT 和 MRI 是评估肝脂肪变性和纤维化的核心无创影像手段。
- 影像学对检测、定量和监测肝脂肪变性及后续纤维化至关重要。
- 放射科医生在 MASLD 诊断方法的发展中可发挥关键作用。
核心结论
- 影像学对检测、定量和监测肝脂肪变性及纤维化至关重要,放射科医生在 MASLD 诊断方法的发展中可发挥关键作用。
研究设计与样本
- 综述,总结了多种影像模态在肝脂肪变性和纤维化无创评估中的原理、临床应用、效能及进展,重点为超声、CT 和 MRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is the fastest-growing cause of chronic liver disease worldwide, affecting approximately 30% of the global population. Imaging is vital for detecting, quantifying, and monitoring hepatic steatosis-the defining abnormality of MASLD-and subsequent fibrosis-the key determinant of liver-related outcomes. This review summarizes the principles, clinical usage, efficacy, and advancements in various imaging modalities for the noninvasive assessment of hepatic steatosis and fibrosis, with an emphasis on ultrasound, CT, and MRI. Additionally, this review explores the evolving landscape of MASLD diagnostic approaches, including machine-learning techniques, opportunistic screening, standardized imaging guidelines, and therapies, emphasizing the pivotal role that radiologists can play in shaping these developments.
引用
- Chan SM, Martins VF, Marsh K, et al. Imaging Evaluation for Steatotic Liver Disease. Korean J Radiol. 2026. PMID: 41494787. doi:10.3348/kjr.2025.0966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。